Annual influenza vaccination is recommended for everyone age 6 months and older as the best way to prevent influenza (flu) and related complications. Flu vaccines are updated annually to protect against the influenza viruses that research indicates will be most common during the upcoming season. Even in cases when vaccination does not prevent infection, it can reduce the severity of disease and prevent serious flu-related complications, including hospitalization and death.
There are several types of flu vaccines offered at many convenient locations, including physician offices, public health departments, pharmacies and retail stores, workplaces, and schools. Many insurance plans pay for annual flu vaccination. Individuals covered by Medicare Part B can get a flu vaccine at no cost (no co-pay, no deductible). Health experts advise not to delay if your first choice of vaccine is not available.
What types of flu vaccines are available?
The Centers for Disease Control and Prevention (CDC) recommends the use of licensed, age-appropriate influenza (flu) vaccines. Options include inactivated influenza vaccines [IIV4], recombinant influenza vaccine [RIV4], and live attenuated influenza vaccine (LAIV4). Different vaccines are licensed for different age groups, and some vaccines are not recommended for certain groups of people.
All flu vaccines available in the US for the 2022-2023 season are quadrivalent vaccines, which are designed to protect against four different flu viruses—two influenza A viruses and two influenza B viruses.
New for the 2022-2023 flu season, 3 flu vaccines are preferentially recommended for adults age 65 years and older:
- Quadrivalent high-dose inactivated flu vaccine
- Quadrivalent recombinant flu vaccine
- Quadrivalent adjuvanted inactivated flu vaccine
If none of these three preferentially recommended flu vaccines is available, adults age 65 years and older should get any other age-appropriate flu vaccine instead.
Flu vaccines available in the US include:
- Standard-dose flu vaccines without adjuvant, manufactured using virus grown in eggs, and approved for individuals age 6 months and older, as an intramuscular injection
- Cell-based standard-dose flu vaccine without adjuvants, which contains virus grown in cell culture, and approved for individuals age 6 months and older, as an intramuscular injection
- Inactivated flu vaccines preferentially recommended for adults age 65 years and older, as an intramuscular injection:
- High-dose, egg-based influenza vaccine (which has 4 times the antigen compared with a standard-dose inactivated influenza vaccine)
- Standard-dose, adjuvanted egg-based influenza vaccine
- Recombinant flu vaccine (made without influenza viruses or eggs), approved for individuals age 18 years and older as an intramuscular injection, and one of the three preferentially recommended influenza vaccines for adults age 65 years and older (this vaccine has 3 times the antigen compared with a standard-dose inactivated flu vaccine)
- Live attenuated influenza nasal spray vaccine (LAIV4) made with attenuated (weakened) live flu viruses, approved for use in individuals age 2 years through 49 years. This vaccine is not recommended for use in pregnant women or in individuals with certain medical conditions.
Influenza vaccine should be used with caution in anyone with a history of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine dose.
Flu and COVID-19:
COVID-19 vaccines and flu vaccines may be administered at the same time.
Influenza vaccines are not designed to prevent COVID-19 infection, and COVID-19 vaccines are not designed to prevent influenza infection. Both vaccines must be received in order to help provide protection against both of these potentially serious respiratory infections.
For more information on flu vaccines and manufacturers, visit www.cdc.gov/flu/professionals/acip/2022-2023/acip-table.htm
For current guidance, see Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2022-2023 Influenza Season. MMWR Recomm Rep 2022;71(No. RR-1):1–28. DOI: http://dx.doi.org/10.15585/mmwr.rr7101a1
Updated October 2022
Source: Centers for Disease Control and Prevention